The safety of daclatasvir for the treatment of hepatitis C

Introduction: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against hepatitis C. Areas covered: We review current literature including published abstracts and manuscripts. Evidence was obtained through PubMed/Medline search using listed keywords and through review of published abstracts. Expert opinion: Daclatasvir introduces a degree of pangenotypic potency currently lacking in other NS5A agents. Emerging literature suggests that daclatasvir in combination with other DAAs will represent a promising option in this difficult to treat populations including posttransplant, genotype 3 and HIV patients.

[1]  D. Dieterich,et al.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.

[2]  V. de Lédinghen,et al.  Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. , 2015, JAMA.

[3]  G. Dore,et al.  Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. , 2015, JAMA.

[4]  P. Thuluvath,et al.  All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.

[5]  M. Manns,et al.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study , 2014, The Lancet.

[6]  F. Penin,et al.  Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. , 2014, Gastroenterology.

[7]  R. Poole.  Daclatasvir + Asunaprevir: First Global Approval , 2014, Drugs.

[8]  E. Asante-Appiah,et al.  Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. , 2014, Gastroenterology.

[9]  O. Weiland,et al.  Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study , 2014, Gut.

[10]  R. Bertz,et al.  Effect of the Coadministration of Daclatasvir on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate , 2014, Antiviral therapy.

[11]  B. Kienzle,et al.  Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity , 2014, Antimicrobial Agents and Chemotherapy.

[12]  X. Forns,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[13]  T. Hassanein,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[14]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[15]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[16]  J. Pawlotsky.  New hepatitis C therapies: the toolbox, strategies, and challenges. , 2014, Gastroenterology.

[17]  M. Manns,et al.  Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials , 2014 .

[18]  O. Weiland,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[19]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[20]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[21]  A. Lok,et al.  Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. , 2014, Journal of hepatology.

[22]  James O Lloyd-Smith,et al.  Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. , 2014, The Journal of antimicrobial chemotherapy.

[23]  T. Asselah,et al.  HCV direct‐acting antiviral agents: the best interferon‐free combinations , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[24]  P. Thuluvath,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[25]  M. Bourlière,et al.  Chronic hepatitis C: future treatment , 2014, Clinical pharmacology : advances and applications.

[26]  R. Bertz,et al.  Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir , 2013, Antiviral therapy.

[27]  T. Eley,et al.  Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir , 2013, Hepatology.

[28]  Nihar Shah,et al.  Review of direct-acting antiviral agents for the treatment of chronic hepatitis C , 2013, Expert opinion on investigational drugs.

[29]  A. Aghemo,et al.  Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. , 2013, Gastroenterology.

[30]  Kenji Ikeda,et al.  Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. , 2013, Journal of hepatology.

[31]  Kenji Ikeda,et al.  Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. , 2013, Journal of hepatology.

[32]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[33]  I. Jacobson,et al.  1203 SAFETY PROFILE OF DACLATASVIR IN COMBINATION WITH PEGINTERFERON alfa AND RIBAVIRIN IN 1100 PATIENTS WITH CHRONIC HCV INFECTION TREATED IN PHASE 2 STUDIES , 2013 .

[34]  G. Dore,et al.  PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL , 2013 .

[35]  M. Manns,et al.  1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL , 2013 .

[36]  M. Gao,et al.  Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir , 2013, Antimicrobial Agents and Chemotherapy.

[37]  T. Asselah,et al.  Interferon free therapy with direct acting antivirals for HCV , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[38]  P. Targett-Adams,et al.  Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. , 2012, Virus research.

[39]  P. Thuluvath,et al.  Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. , 2012, The Lancet. Infectious diseases.

[40]  Xin Huang,et al.  Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.

[41]  D. Grasela,et al.  Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 , 2011, Hepatology.

[42]  F. Negro,et al.  The global health burden of hepatitis C virus infection , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[43]  F. Sanai,et al.  A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[44]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[45]  M. Buti,et al.  A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[46]  M. Elazar,et al.  The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. , 2011, Virology.

[47]  M. Gao,et al.  Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052 , 2011, Journal of Virology.

[48]  Min Gao,et al.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.

[49]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[50]  U. Koch,et al.  Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. , 2009, Bioorganic & medicinal chemistry letters.

[51]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[52]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[53]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[54]  H. Margolis,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[55]  H. Bohorquez,et al.  Post-transplant Treatment of Severe Recurrent Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus or Minus Ribavirin , 2014 .

[56]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[57]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.